Lisa Bero

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Priority medicines for maternal and child health: a global survey of national essential medicines lists
    Suzanne Hill
    Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    PLoS ONE 7:e38055. 2012
  2. pmc Factors associated with results and conclusions of trials of thiazolidinediones
    Gail Rattinger
    Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland at Baltimore, Baltimore, Maryland, United States of America
    PLoS ONE 4:e5826. 2009
  3. pmc Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis
    David Krauth
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, United States of America
    PLoS Biol 12:e1001770. 2014
  4. pmc Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia
    Pille Taba
    Department of Continuing Medical Education, University of Tartu, Puusepa 8, Tartu, 51014, Estonia
    BMC Health Serv Res 12:455. 2012
  5. doi request reprint The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines
    Lisa A Bero
    Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA 94118, USA
    J Clin Epidemiol 66:132-9. 2013
  6. pmc Association of trial registration with the results and conclusions of published trials of new oncology drugs
    Nicolas Rasmussen
    History and Philosophy of Science, University of New South Wales, Sydney 2052, Australia
    Trials 10:116. 2009
  7. pmc Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors
    Monica Smith
    Palmer Center for Chiropractic Research, Palmer College of Chiropractic, Davenport, IA, USA
    Chiropr Osteopat 18:30. 2010
  8. pmc Evidence and argument in policymaking: development of workplace smoking legislation
    Dorie E Apollonio
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143 0613, USA
    BMC Public Health 9:189. 2009
  9. pmc Implementation of a workplace smoking ban in bars: the limits of local discretion
    Theresa Montini
    New York University, 423 East 23rd Street, VET 16N, New York, NY 10010, USA
    BMC Public Health 8:402. 2008
  10. pmc Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia
    Anna L Ridge
    Medicine Access and Rational Use, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    BMC Health Serv Res 10:340. 2010

Collaborators

Detail Information

Publications31

  1. pmc Priority medicines for maternal and child health: a global survey of national essential medicines lists
    Suzanne Hill
    Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    PLoS ONE 7:e38055. 2012
    ..The objective of this study was to examine the occurrence of these priority medicines on national essential medicines lists...
  2. pmc Factors associated with results and conclusions of trials of thiazolidinediones
    Gail Rattinger
    Department of Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland at Baltimore, Baltimore, Maryland, United States of America
    PLoS ONE 4:e5826. 2009
    ....
  3. pmc Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis
    David Krauth
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, United States of America
    PLoS Biol 12:e1001770. 2014
    ..Possible reasons for the differences between nonindustry- and industry-sponsored studies, such as selective reporting of outcomes, require further study. ..
  4. pmc Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia
    Pille Taba
    Department of Continuing Medical Education, University of Tartu, Puusepa 8, Tartu, 51014, Estonia
    BMC Health Serv Res 12:455. 2012
    ..The study was conducted to inform the revision of the clinical practice guideline development process and can provide inspiration to other countries considering the increasing use of evidence-based medicine...
  5. doi request reprint The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines
    Lisa A Bero
    Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA 94118, USA
    J Clin Epidemiol 66:132-9. 2013
    ..This experience may be relevant to other small or resource-limited countries...
  6. pmc Association of trial registration with the results and conclusions of published trials of new oncology drugs
    Nicolas Rasmussen
    History and Philosophy of Science, University of New South Wales, Sydney 2052, Australia
    Trials 10:116. 2009
    ..This study compares the prevalence of favorable results and conclusions among published reports of registered and unregistered randomized controlled trials of new oncology drugs...
  7. pmc Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors
    Monica Smith
    Palmer Center for Chiropractic Research, Palmer College of Chiropractic, Davenport, IA, USA
    Chiropr Osteopat 18:30. 2010
    ....
  8. pmc Evidence and argument in policymaking: development of workplace smoking legislation
    Dorie E Apollonio
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143 0613, USA
    BMC Public Health 9:189. 2009
    ..We sought to identify factors that affect the passage of public health legislation by examining the use of arguments, particularly arguments presenting research evidence, in legislative debates regarding workplace smoking restrictions...
  9. pmc Implementation of a workplace smoking ban in bars: the limits of local discretion
    Theresa Montini
    New York University, 423 East 23rd Street, VET 16N, New York, NY 10010, USA
    BMC Public Health 8:402. 2008
    ..In January 1998, the California state legislature extended a workplace smoking ban to bars. The purpose of this study was to explore the conditions that facilitate or hinder compliance with a smoking ban in bars...
  10. pmc Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia
    Anna L Ridge
    Medicine Access and Rational Use, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    BMC Health Serv Res 10:340. 2010
    ..The objective of this study was to identify barriers to the availability and use of MgSO4 in the Zambian Public Health System...
  11. pmc To give is better than to receive: compliance with WHO guidelines for drug donations during 2000-2008
    Lisa Bero
    Department of Clinical Pharmacy, University of California, 3333 California Street Suite 420, San Francisco, CA 94118, United States of America
    Bull World Health Organ 88:922-9. 2010
    ..to assess drug donations in terms of their adherence to the drug donation guidelines put forth by the World Health Organization (WHO)...
  12. pmc Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others
    Lisa Bero
    Clinical Pharmacy and Health Policy, University of California, San Francisco, California, United States of America
    PLoS Med 4:e184. 2007
    ....
  13. doi request reprint "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterprise
    Lisa Bero
    University of California, Clinical Pharmacy and Health Policy, 3333 California Street, Suite 420, San Francisco, CA, USA
    J Clin Epidemiol 61:629-33. 2008
  14. pmc Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review
    David Krauth
    Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA 94118, USA
    Environ Health Perspect 121:985-92. 2013
    ..However, there is significant debate about how to evaluate the methodology and potential biases of the animal studies. There is no agreed-upon approach, and a systematic evaluation of current best practices is lacking...
  15. doi request reprint An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciences
    Tracey J Woodruff
    University of California, San Francisco, CA, USA
    Health Aff (Millwood) 30:931-7. 2011
    ..The methodology can also support professional societies, health care organizations, government agencies, and others in developing prevention-oriented guidelines for use in clinical and policy settings...
  16. doi request reprint Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses
    BETH HART
    Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, 3333 California St, Suite 420, San Francisco, CA 94118, USA
    BMJ 344:d7202. 2012
    ..To investigate the effect of including unpublished trial outcome data obtained from the Food and Drug Administration (FDA) on the results of meta-analyses of drug trials...
  17. pmc Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation
    Kristin Rising
    School of Medicine, University of California San Francisco, San Francisco, California, USA
    PLoS Med 5:e217; discussion e217. 2008
    ....
  18. doi request reprint Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes
    Nancy Nkansah
    University of California San Francisco, 155 North Fresno Street Suite 224, Fresno, CA 93701, USA
    Public Health Nutr 12:1931-7. 2009
    ..To explore the relationship between industry sponsorship of Ca supplementation studies in healthy children and study outcomes...
  19. pmc Interactions between non-physician clinicians and industry: a systematic review
    Quinn Grundy
    Department of Social and Behavioral Sciences, School of Nursing, University of California, San Francisco, San Francisco, California, United States of America
    PLoS Med 10:e1001561. 2013
    ..The purpose of this systematic review is to examine the types and implications of non-physician clinician-industry interactions in clinical practice...
  20. pmc Strategies for obtaining unpublished drug trial data: a qualitative interview study
    Nicole Wolfe
    Department of Social and Behavioral Sciences, University of California, San Francisco, CA 94118, USA
    Syst Rev 2:31. 2013
    ....
  21. doi request reprint Medicaid drug selection committees and inadequate management of conflicts of interest
    Nicole Yvonne Nguyen
    Department of Clinical Pharmacy and Institute for Health Policy Studies, University of California, San Francisco, 3333 California St, San Francisco, CA 94118, USA
    JAMA Intern Med 173:338-43. 2013
    ....
  22. ncbi request reprint Financial ties and conflicts of interest between pharmaceutical and tobacco companies
    Bhavna Shamasunder
    Institute for Health Policy Studies, University of California, San Francisco, USA
    JAMA 288:738-44. 2002
    ..Thus, because tobacco cessation product marketing has been altered as a result of these financial conflicts, disclosure would serve the interest of public health...
  23. ncbi request reprint Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds
    Jenny White
    Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
    Nicotine Tob Res 9:1213-25. 2007
    ..Policymakers should consider expanding the scope of federal human subjects research regulations to cover research undertaken by private firms such as tobacco companies...
  24. ncbi request reprint Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials
    Andrew Anglemyer
    Global Health Sciences, University of California, San Francisco, San Francisco, California, USA, 94105
    Cochrane Database Syst Rev 4:MR000034. 2014
    ....
  25. doi request reprint Outcome reporting in industry-sponsored trials of gabapentin for off-label use
    S Swaroop Vedula
    Center for Clinical Trials, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    N Engl J Med 361:1963-71. 2009
    ..There is good evidence of selective outcome reporting in published reports of randomized trials...
  26. pmc Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala
    Angela Anson
    Department of Clinical Pharmacy, University of California, San Francisco, CA 94143 0622, USA
    Global Health 8:22. 2012
    ..A first step in achieving this goal is to obtain a baseline measure of access to essential medicines. The objective of this project was to measure the availability, prices, and affordability of children's medicines in Guatemala...
  27. ncbi request reprint Implications of the tobacco industry documents for public health and policy
    Lisa Bero
    Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, California 94143 0613, USA
    Annu Rev Public Health 24:267-88. 2003
    ..The paper concludes with a discussion of the implications of tobacco document research for public health and the application of such research to fields other than tobacco control...
  28. pmc Applying the essential medicines concept to US preferred drug lists
    Timothy P Millar
    Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
    Am J Public Health 101:1444-8. 2011
    ..We also characterized listed medicines by generic availability and appearance on treatment guidelines...
  29. ncbi request reprint Clarification of study and citation
    Patrick R Finley
    Arch Intern Med 167:2531; author reply 2531-2. 2007